Innovent Biologics
China - JiangsuBiotechnology
Focus: Innovent Biologics is a China-based biotechnology company specializing in monoclonal antibodies and biosimilars across oncology, metabolic diseases, immunology, ophthalmology, and endocrinology. The company maintains a diversified pipeline with 30 active programs spanning Phase 1 through Phase 3 development.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Innovent Biologics
AI assessmentNot HiringNo open roles listed right now. Follow Innovent Biologics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Intense Monitoring Study on Tyvyt
Relapsed or Refractory Classical Hodgkin's LymphomaClinical Trials (1)
NCT04237233Intense Monitoring Study on Tyvyt
N/AHelp build intelligence for Innovent Biologics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.